Trials / Terminated
TerminatedNCT00301431
Study Evaluating the Efficacy of DVS-233 in Fibromyalgia
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Adaptive Design, Efficacy and Tolerability Study of 4 Fixed Doses of DVS-233 in Adult Outpatients With Fibromyalgia Syndrome
- Status
- Terminated
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 1,050 (planned)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine if DVS-233 is safe and effective in the treatment of pain and other symptoms of fibromyalgia syndrome.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | DVS-233 |
Timeline
- Start date
- 2006-08-01
- Completion
- 2007-06-01
- First posted
- 2006-03-10
- Last updated
- 2007-12-05
Locations
59 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00301431. Inclusion in this directory is not an endorsement.